Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer
Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The investigators propose to initiate a study assessing the efficacy and safety of a lower initial dosage of lenvatinib combined with toripalimab in patients suffering from platinum-resistant recurrent ovarian cancer. The objective of this research is to offer a novel therapeutic approach for patients battling relapsed ovarian cancer with platinum resistance.
Phase:
PHASE2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The Second Affiliated Hospital of Dalian Medical University